3.67
+0.07(+1.94%)
Currency In USD
| Previous Close | 3.6 |
| Open | 3.62 |
| Day High | 3.69 |
| Day Low | 3.55 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.33 |
| Volume | 199,041 |
| Average Volume | 722,196 |
| Market Cap | 113.9M |
| PE | -30.58 |
| EPS | -0.12 |
| Moving Average 50 Days | 2.77 |
| Moving Average 200 Days | 2.29 |
| Change | 0.07 |
If you invested $1000 in Fortress Biotech, Inc. (FBIO) 10 years ago, it would be worth $85.85 as of December 25, 2025 at a share price of $3.67. Whereas If you bought $1000 worth of Fortress Biotech, Inc. (FBIO) shares 5 years ago, it would be worth $77.18 as of December 25, 2025 at a share price of $3.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission
GlobeNewswire Inc.
Dec 15, 2025 1:00 PM GMT
New PDUFA Target Action Date of January 14, 2026 set by FDAMIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that t
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
GlobeNewswire Inc.
Oct 21, 2025 12:30 PM GMT
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
GlobeNewswire Inc.
Oct 01, 2025 12:05 PM GMT
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of